Abbott Laboratories is voluntarily withdrawing sibutramine from the market based on an increased risk of myocardial infarction and stroke in those taking the drug, a risk that outweighs “any benefit from the modest weight loss observed with the drug,” the Food and Drug Administration announced Oct. 8.
